The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients experiencing facial volume loss following medication-driven weight loss, according to ...

A new report says only using BMI to determine if a patient has obesity leads to under-diagnosing people who are ill and ...

The GLP-1 [glucagon-like peptide 1] agents are poised to become viable options for treating indications beyond type 2 ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

At the J.P. Morgan Health Care conference, the future outlook for GLP-1 drugs used to treat obesity was a key focus, ...

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.

This is just a glimpse of the insights available to CivicScience clients. Want to see the full picture? Let’s talk. As the ...

Professor Joe Balagtas explains how drugs like Ozempic impact appetite. Purdue’s Center for Food Demand Analysis and ...

In its first financial results since its insurance unit CEO was fatally shot in New York City, UnitedHealth Group reported ...

The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in ...